INBX · Inhibrx Biosciences, Inc.

$84.09 -3.30 (-3.78%) At close · Jul 20

Market Cap

$1.23B

14.67M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark P. Lappe	CEO	$695,250	$1,700,000	—	—	$479,723	$17,500	$2,892,473
David J. Matly	President	$589,170	—	—	$524,285	$304,985	$17,500	$1,435,940
Kelly D. Deck	CFO	$493,485	—	—	$157,286	$255,425	$17,500	$923,696

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark P. Lappe	CEO	$695,250	—	—	$3,573,408	$417,150	$5,975	$4,691,783
Kelly D. Deck	CFO	$460,100	$1,500,000	—	$2,084,488	$207,045	$15,621	$4,267,254
Brendan P. Eckelman	Former Chief Scientific Officer	$535,600	—	—	$2,084,488	—	$7,504	$2,627,592

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mark P. Lappe	CEO	$675,000	—	—	$1,706,771	$405,000	$15,250	$2,802,021
Brendan P. Eckelman	Former Chief Scientific Officer	$520,000	—	—	$682,708	$234,000	$15,250	$1,451,958
Kelly D. Deck	CFO	$430,000	—	—	$512,031	$193,500	$13,368	$1,148,899

Key facts CIK 2007919 CUSIP 45720N103 13F (30d) 10 filings 10 filers Visit website